Title: How Is AI Optimizing Different Aspects of FDA Submissions?
1- How Is AI Optimizing Different Aspects of FDA
Submissions? - The Department of Health and Human Services
Regulatory agency is known as The Food and Drug
Administration. The FDA is accountable for
protecting and promoting public health through
controlling and supervising food safety, tobacco
products, dietary supplements, prescription and
over-the-counter pharmaceutical drugs
(medications), vaccines, biopharmaceuticals,
blood transfusions, and medical devices. FDA
approval is a must for any drug to be on the
market. FDA plays a crucial role in reviewing
drugs, medical devices, and biologics before it
enters the market. - The development of pharmaceuticals is a complex
and lengthy process. Companies abide by the
regulatory bodys guidelines for the
effectiveness of the drugs, vaccines, biologics,
and medical devices, for which FDA submission is
essential and crucial in several steps. Nowadays,
companies are leveraging artificial intelligence
for effective and quick submissions. The FDA is
also developing a new regulatory framework to
promote innovation and support AI-based
technologies. - A New Strategy of the FDA in Leveraging AI
- In 2017, the FDA announced a Digital Health
Innovation Action Plan to outline its strategy
to implement useful healthcare technologies and
promote AI-based applications in research and
development. Furthermore, the FDA is encouraging
initiatives to develop and implement advanced
predictive models in streamlining the drug review
process. With an adequate regulatory framework,
safe and effective therapies can be discovered,
developed, and marketed much faster than ever. - Traditionally, the FDA evaluates medical devices
through a suitable premarket pathway, such as De
Novo classification or premarket approval. The
FDA may also analyze and clear modifications to
medical devices, including software as a medical
device, depending on the importance of risk
posed to patients by that modification. Learn the
current FDA guidance for a risk-based approach
for 510(k) software modifications. The FDAs
traditional medical device regulation paradigm
was not intended for adaptive artificial
intelligence and machine learning technologies.
Under the FDAs current approach to software
changes, the FDA anticipates that many
artificial intelligence and machine
learning-driven software modifications to a
device need a premarket review. - On April 2nd, 2019, the FDA issued a paper,
Proposed Regulatory Framework for Modifications
to Artificial Intelligence/Machine Learning
(AI/ML)-Based Software as a Medical Device
(SaMD) Discussion Paper and Request for
Feedback. This explains the FDAs foundation
for a possible way to premarket review for
artificial intelligence and machine
learning-driven software modifications.
2For more information, please visit _at_
https//www.iebrain.com/how-is-ai-optimizing-diffe
rent- aspects-of-fda-submissions/ About
Ingenious e-Brain Solutions - Ingenious e-Brain
Solutions provides high-quality, customized, and
cost-effective Technology Intelligence, Business
Intelligence, and Intellectual Property
Intelligence solutions to industry leaders, and
innovative companies across the globe.
Innovation, knowledge, and transparency form the
basis of our companys mission and vision. Along
with cost benefits, we provide highest quality
results ensuring fool-proof confidentiality and
security. We are an ISO certified company with
offices in India and USA. Ingenious e-Brain
Solutions has a strong team of analysts, and
subject matter experts with domain proficiency
which is devoted to help clients grow. Our highly
qualified professionals offer tailored,
value-added and cost-effective services to our
clients. We believe in building long term
relationships with our clients who include
national and international corporations, Fortune
500 companies, worlds leading research
institutes and universities as well as
independent inventors. Get in Touch - India
Office 207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, India 91
124 429 4218 Email - queries_at_iebrain.com